ArticleClinical ophthalmology (Auckland, N.Z.)2026
Management of Stage 1 Neurotrophic Keratopathy with Shelf-Stable, Cryopreserved Amniotic Membrane: A Retrospective Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess whether shelf-stable, cryopreserved amniotic membrane (CAM) can improve clinical signs and symptoms in patients with early-stage neurotrophic keratopathy (NK). Methods: A multiple-center, retrospective study of patients with early-stage NK who failed prior conservative therapies and were subsequently treated with shelf-stable CAM and a 24-hour collagen shield. NK was defined as the presence of superficial punctate keratopathy in conjunction with reduced corneal sensitivity (Mackie stage 1) in the central corneal zone measured with a cotton-wisp. Tear break up time (TBUT), corneal staining, symptoms, best corrected visual acuity (BCVA), and corneal sensitivity were assessed at baseline, 1-week, 1-month, and 3-months. Results: A total of 18 eyes of 13 patients met the eligibility criteria and were included for analysis. At baseline, the mean corneal staining score, TBUT, and BCVA logMAR were 1.69 ± 0.79, 3.1 ± 1.8 seconds, and 0.32 ± 0.19, respectively. At 10.5 ± 4.9 days, corneal staining, TBUT, and BCVA significantly improved. A total of 61.5% of eyes had no epitheliopathy and corneal sensitivity was normal in 9.1% of eyes. At 31.2 ± 10.8 days, corneal sensitivity was normal in 73.3% of eyes, and corneal staining scores, TBUT, and BCVA significantly improved. A total of 11 eyes (73.3%) had no epitheliopathy. At 14.7 ± 3.7 weeks, corneal sensitivity was normal in 61.5% of eyes. Corneal staining significantly improved to 0.43 ± 0.43 (p < 0.001), TBUT significantly improved to 6.5 ± 2.4 s (p = 0.005), and BCVA logMAR was 0.21 ± 0.24 (p = 0.13). Conclusion: This exploratory retrospective study suggests that treatment with shelf-stable CAM may improve corneal epithelial integrity, visual acuity, and corneal sensitivity in patients with early-stage NK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.